89bio — Investor Presentation (June 2021)
41 slides from 89bio's investor presentation, Jun 10, 2021
Slide 1: Powerful Science, Meaningful Medicines, Changing Lives
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives June 2021 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of his
Slide 3: 89bio - Investment Highlights
89bio - Investment Highlights Highly differentiated FGF21 using GlycoPEGylation technology to optimize efficacy and dosing Validated with compelling profile: strong efficacy, favorable safety/tolerability, and potential best-in-class dosing BIO89-100 has potential to be a leading DRUG FOR LIVER AND
Slide 4: Advancing BIO89-100 in Clinical Development
Indication Preclinical Phase 1 Phase 2 Phase 3 NASH SHTG Phase 1b/2a histology cohort Advancing BIO89-100 in Clinical Development Phase 2b trial Phase 2 trial Phase 2 fibrate cohort
Slide 5: Opportunity in NASH
Opportunity in NASH
Slide 6: NASH is a Serious Liver Condition With Significant Co-Morbidities
NASH is a Serious Liver Condition With Significant Co-Morbidities No treatments currently available 16.5 million cases projected to grow to 27 million cases by 2030 Expected to become the leading cause of liver transplant Co-morbidity Prevalence in NASH population Hypertriglyceridemia 83% Obesity 82
Slide 7: FGF21 Has Potential To Be Mainstay of Therapy In NASH
FGF21 Has Potential To Be Mainstay of Therapy In NASH Endogenous metabolic hormone that regulates energy expenditure and glucose and lipid metabolism Reduces liver fat by action within liver and from periphery Impacts liver fibrosis via metabolic pathway and upregulation of adiponectin Native FGF21
Slide 8: BIO89-100 Is An FGF21 Optimally Engineered for Efficacy and Long Dosing Interval
BIO89-100 Is An FGF21 Optimally Engineered To Balance Potential for Efficacy and Long Dosing Interval glycoPEG(20kD) C-terminus X Strong and flexible linker (glycoPEGylation technology) Mutations in positions 173 and 176 (glycoPEG attached at position 173) X N-terminus Position 182 FGF21 Proprietary
Slide 9: Phase 1b/2a NASH Trial Design
Phase 1b/2a NASH Trial Design MRI-PDFF SCREENING RANDOMIZATION Wk 12 NASH* or phenotypic NASH (PNASH)# PDFF≥10% *Patients with biopsy-proven F1-3 #Central obesity plus T2DM or evidence of liver injury KEY INCLUSION CRITERIA Safety, PK Relative changes in liver fat Serum lipids, liver and metabolic m
Slide 10: Majority of Patients on BIO89-100 Achieved ≥50% Reduction in Liver Fat
Majority of Patients on BIO89-100 Achieved ≥50% Reduction in Liver Fat MRI Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo; placebo relative increase of 10% from baseline ^ 60% relative reduction in liver fat vs. placebo when final 2 patients from this dose group were exc
Slide 11: Significant Numbers of Patients Achieved Clinically Meaningful Responder Rates
Up to 43% of patients normalized their liver fat (<5%) ≥30% relative reduction in liver fat has been correlated with NASH resolution and fibrosis improvement 71% of patients on 27 mg QW dose had ≥70% relative reduction in liver fat Significant Numbers of Patients Achieved Clinically Meaningful Respo
Slide 12: BIO89-100 Significantly Reduced Liver Fat Across All Dose Groups
Baseline characteristics were similar between NASH and PNASH patients Reductions in absolute percentage of liver fat from baseline, % responders on MRI-PDFF and BIO89-100’s effect on reducing ALT and TGs were also similar across NASH and PNASH patients BIO89-100 Significantly Reduced Liver Fat Acros
Slide 13: BIO89-100 Significantly Reduced ALT in Patients with Elevated Baseline ALT
BIO89-100 Significantly Reduced ALT with Greater Reduction Observed in Patients with Elevated Baseline ALT *** * * *** Percent Change from Baseline at Week 13 -30 U/L -22 U/L Q2W QW Absolute change: n=5 n=17 Placebo Pooled BIO89-100 * Absolute Change in ALT at Week 13 (Baseline ALT > 45 U/L) PD Anal
Slide 14: BIO89-100 Significantly Reduced Triglycerides
Decrease from baseline in BIO89-100 treated subgroup with baseline TG ≥200 mg/dL TG: 33%-49% Non-HDL: 8%-29% BIO89-100 Significantly Reduced Triglycerides with Greater Benefit Observed in Patients with High Triglycerides PD Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo;
Slide 15: BIO89-100 (27 mg QW) Improved Metabolic Markers
BIO89-100 (27 mg QW) Improved Metabolic Markers *** * HbA1c (%) placebo adjusted change from baseline = -0.3 PD Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo. Placebo HOMA-IR: -0.1%; Glucose: +7.9%; HbA1c +0.61%; Weight: +1.4% Adiponectin: -4.3%
Slide 16: BIO89-100 Demonstrated a Favorable Safety Profile
BIO89-100 Demonstrated a Favorable Safety Profile Treatment Emergent Adverse Event (TEAE) Placebo (n=18) 3mg QW (n=7) 9mg QW (n=12) 18mg QW (n=11) 27mg QW (n=10) 18mg Q2W (n=14) 36mg Q2W (n=9) TEAE Leading to Death 0 0 0 0 0 0 0 TEAE Leading to Discontinuation 0 0 0 0 1a 1b 0 Serious Adverse Event C
Slide 17: BIO89-100 Was Well Tolerated Across Doses
BIO89-100 Was Well Tolerated Across Doses Low Incidence of Treatment-Related Emergent AEs in ≥ 10% of Pooled BIO89-100 Group Preferred Term n (%) Placebo (n=18) Pooled BIO89-100 (n=63) 3mg QW (n=7) 9mg QW (n=12) 18mg QW (n=11) 27mg QW (n=10) 18mg Q2W (n=14) 36mg Q2W (n=9) Increased Appetite 0.0% 15.
Slide 18: Phase 1b/2a NASH Open-label Histology Cohort Trial Design
Phase 1b/2a NASH Open-label Histology Cohort Trial Design F2-F3* NASH; NAS ≥4 MRI-PDFF ≥8% KEY INCLUSION CRITERIA Liver Biopsy SCREENING Wk 20 SAFETY FOLLOW-UP 27mg QW BIO89-100 B B Fibrosis Improvement NASH Resolution Liver fat (MRI-PDFF) Non-invasive tests KEY SECONDARY ENDPOINTS PRIMARY ENDPOINT
Slide 19: Phase 2b (ENLIVEN) NASH Trial Design
Phase 2b (ENLIVEN) NASH Trial Design F2-F3 NASH; NAS ≥4 MRI-PDFF ≥8% KEY INCLUSION CRITERIA Other histological endpoints NITs – Pro-C3, ELF, FIB-4 cT1 Lipid and metabolic assessments Liver fat (MRI-PDFF) Safety OTHER ENDPOINTS Fibrosis Improvement NASH Resolution PRIMARY ENDPOINTS SCREENING RANDOMIZ
Slide 20: Comparative Profile of FGF21 Analogs
Comparative Profile of FGF21 Analogs BIO89-100 Efruxifermin Pegbelfermin Structure GlycoPEGylated FGF21 Fc-fused FGF21 PEGylated FGF21 (with non-native amino acid substitution) Efficacy Significant effect on liver parameters Robust impact on broad metabolic parameters EFX demonstrated positive data
Slide 21: Opportunity in SHTG
Opportunity in SHTG
Slide 22: SHTG Market Is Large with Significant Unmet Need
Diagnosis and treatment rates expected to increase in the future SHTG Market Is Large with Significant Unmet Need * 50% is based on registrational trials of Vascepa and Epanova (at 4mg/day dose) approved in SHTG LARGE PATIENT POPULATION WITH HIGH UNMET NEED AND MULTIPLE CO-MORBIDITIES Estimated up t
Slide 23: Current Therapies Reached Blockbuster Status Despite Falling Short on Safety and Co-Morbidities
FISH OILS FIBRATES Vascepa (EPA) Lovaza (EPA+DHA) Tricor Reduce Hepatic Fat - - - Improve LDL-C - Worsens LDL Worsens LDL ALT - Warnings, Monitoring Required Glycemic Control - - - Tolerability/ Safety May prolong bleeding time Myopathy, Creatinine increases, DDI Current Therapies Reached Blockbuste
Slide 24: BIO89-100 Significantly Reduced Triglycerides with Greater Benefit in High Triglycerides
Decrease from baseline in BIO89-100 treated subgroup with baseline TG ≥200 mg/dL TG: 33%-49% Non-HDL: 8%-29% BIO89-100 Significantly Reduced Triglycerides with Greater Benefit Observed in Patients with High Triglycerides PD Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo;
Slide 25: Physicians Research Showed Strong Interest in Broad Metabolic Profile of BIO89-100
Physicians Research Showed Strong Interest in the Broad Metabolic Profile of BIO89-100 for Their SHTG Patients 30% TG reduction as add on 50% TG reduction as monotherapy 30% TG reduction as add on Parameter Meaningful Chg. in Parameter Share* for Meaningful Change + TG Reduction Liver fat reduction
Slide 26: ENTRIGUE – Phase 2 SHTG Trial Design
ENTRIGUE – Phase 2 SHTG Trial Design * Based on Vascepa and Epanova programs KEY INCLUSION CRITERIA TG ≥500 mg/dL and ≤2,000 mg/dL Background therapy of statins and/or prescription fish oil OR not on any background therapy Other lipids and metabolic parameters Liver fat (MRI-PDFF) KEY SECONDARY ENDP
Slide 27: ENTRIGUE – Phase 2 SHTG Fibrate Cohort Trial Design
ENTRIGUE – Phase 2 SHTG Fibrate Cohort Trial Design KEY INCLUSION CRITERIA TG ≥500 mg/dL and ≤2,000 mg/dL Background therapy of fibrates Other lipids and metabolic parameters Liver fat (MRI-PDFF) KEY SECONDARY ENDPOINTS % Change in TGs from baseline PRIMARY ENDPOINT SCREENING RANDOMIZATION SAFETY FO
Slide 28: Financial Position Summary
Financial Position Summary Cash, cash equivalents and short-term investments $189.6 million (as of March 31, 2021)
Slide 29: Achievements and Milestones
Achievements and Milestones Phase 2b (ENLIVEN) NASH trial – Ongoing NASH histology results – YE21 Topline results from Phase 2 (ENTRIGUE) SHTG trial – 1H22 ACHIEVEMENTS (~3 Years) PROGRAM STATUS/MILESTONES Significant progress in the clinic: SAD, Phase 1b/2a in NASH, Phase 2 in SHTG, additional coho
Slide 30: 89bio - Investment Highlights
89bio - Investment Highlights Highly differentiated FGF21 using GlycoPEGylation technology to optimize efficacy and dosing Validated with compelling profile: strong efficacy, favorable safety/tolerability, and potential best-in-class dosing BIO89-100 has potential to be a leading DRUG FOR LIVER AND
Slide 31: Appendix
Appendix
Slide 32: Experienced Management Team Positions 89bio for Success
Experienced Management Team Positions 89bio for Success Rohan Palekar CEO CEO, CCO experience Commercial, strategy, and R&D experience Hank Mansbach, MD CMO 20+ years biopharma and R&D leadership in clinical development and medical affairs Ram Waisbourd COO & CBO 20 years of operations, BD, and stra
Slide 33: BIO89-100 Exhibits Highly Potent FGF Receptor Agonism
BIO89-100 Exhibits Highly Potent FGF Receptor Agonism BIO89-100 has the potential to reproduce the beneficial metabolic effects of native FGF21 nd – not determined; rhFGF19 EC50 at FGFR4 = 1.7 ± 0.4 * Receptor agonism measured in L6 cells expressing β-klotho and either FGF Receptor 1c, 2c, 3c, or 4
Slide 34: Baseline Characteristics
Baseline Characteristics Parameter Mean or % Placebo (n=19) Pooled BIO89-100 (n=62) 3mg QW (n=6) 9mg QW (n=12) 18mg QW (n=11) 27mg QW (n=10) 18mg Q2W (n=14) 36mg Q2W (n=9) Age (years) 52.6 51.7 56.1 49.5 51.5 52.0 51.2 52.5 Male/Female 36.8% 38.7% 16.7% 50% 27.3% 20% 28.6% 88.9% Weight (kg) 93.6 93.
Slide 35: Substantial Reduction in Liver Fat and Liver Volume Across Dose Groups
Substantial Reduction in Liver Fat and Liver Volume Across Dose Groups Patient A, 9mg QW Patient C, 18mg Q2W Patient B, 27mg QW Baseline Week 13 LF 25.3% LF 81.4%↓ LV 14.6%↓ LF 79.2%↓ LV 27.7%↓ LF 87.6%↓ LV 35.4%↓ LV 1.9 L LF 41.1% LV 2.2 L LF 4.7% LV 1.6 L LF 5.1% LV 1.4 L LF 16.8% LV 1.2 L LF 3.5%
Slide 36: BIO89-100 Significantly Improves Key Lipid Markers
BIO89-100 Significantly Improves Key Lipid Markers Percentage Change from Baseline At Week 13 PD Analysis Set; MMRM LS Mean; * p<0.05; ** p<0.01; *** p<0.001 versus placebo ** * * * *** * Non-HDL QW Q2W LDL-C HDL-C QW Q2W QW Q2W
Slide 37: BIO89-100 Effect on Glycemic Control
BIO89-100 Effect on Glycemic Control Placebo 3mg QW 9mg QW 18mg QW 27mg QW 18mg Q2W 36mg Q2W Adiponectin % Change -4.3% 37.7%* 25.5%* 29.1%* 60.9%*** 23.1%* 24.1% Insulin& % Change 10.0% -8.5% -9.4% -22.5% -6.9% -39.7% -34.5% HbA1c (%) Absolute Change <0.1 0.6 0.1 0.1 -0.3 -0.1 0.5 No meaningful cha
Slide 38: Similar Baseline Characteristics in Patients with Biopsy-Proven NASH or PNASH
Similar Baseline Characteristics in Patients with Biopsy-Proven NASH or PNASH Parameter NASH PNASH Overall Mean or % (N=15) (N=66) (N=81) Age (years) 50.6 52.2 51.9 Male 20% 42.2% 38.3% Weight (kg) 99.3 92.3 93.6 BMI (kg/m2) 35.4 34.4 34.6 Type 2 Diabetes 26.7% 50% 45.7% ALT (U/L) 42.9 41.1 41.5 ALT
Slide 39: BIO89-100 has Overall Efficacy Comparable to EFX and Superior to Pegbelfermin
BIO89-100 has Overall Efficacy Comparable to EFX and Superior to Pegbelfermin BIO89-100 (12 weeks) EFRUXIFERMIN (16 weeks*) PEGBELFERMIN (16 weeks) All Doses 27mg QW 28mg QW 50mg QW 10mg QD 20mg QW KEY EFFICACY PARAMETERS MRI-PDFF Relative reduction in fat vs. placebo (%) 47-70 70 63 71 32 20 ≥30% R
Slide 40: BIO89-100 has Better Tolerability Profile Compared to EFX
BIO89-100 has Better Tolerability Profile Compared to EFX BIO89-100 (12 weeks) EFRUXIFERMIN* (16 weeks) PEGBELFERMIN (16 weeks) Pooled 27 mg QW 28mg QW 50mg QW 20mg QW 10mg QD SELECTED AEs Treatment Related AEs Treatment Related AEs ≥10% Most Frequent AEs Diarrhea 9.5% 20% 26% 53% 21% 12% Nausea 4.8
Slide 41: FGF21 – Highly Differentiated Mechanism versus Leading Therapeutics in Development for NASH
FGF21 FXR PPAR* THR-β GLP-1 Liver fat reduction ✔ ✔ ✔ ✔ Fibrosis improvement ✔ ✔ ✔ ? Triglyceride reduction ✔ ✔ ✔ LDL-C improvement ✔ Worsens LDL ✔ HDL-C improvement ✔ ✔ Glycemic control ✔ ✔ ✔ Limited Side Effects ✔ GI effect** Pruritis LDL ↑ Weight Gain Edema Drug-drug interaction ✔ GI effect Dosin